Data gathered: June 24
Alternative Data for Zevra Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 9 | Sign up | Sign up | Sign up |
| Sentiment | 98 | Sign up | Sign up | Sign up |
| Webpage traffic | 11,000 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 69 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 23,420 | Sign up | Sign up | Sign up |
| Twitter Followers | 667 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Linkedin Employees | 67 | Sign up | Sign up | Sign up |
About Zevra Therapeutics
Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States.
| Price | $9.00 |
| Target Price | Sign up |
| Volume | 357,420 |
| Market Cap | $494M |
| Year Range | $6.56 - $9.68 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
 |
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives Consensus Rating of “Buy” from AnalystsJune 19 - ETF Daily News |
|
Brokers Issue Forecasts for ZVRA FY2026 EarningsJune 12 - ETF Daily News |
|
Deutsche Bank AG Increases Stock Holdings in Zevra Therapeutics, Inc. (NASDAQ:ZVRA)May 31 - ETF Daily News |
|
25,075 Shares in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Bought by D. E. Shaw & Co. Inc.May 29 - ETF Daily News |
|
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives $22.29 Average Price Target from BrokeragesMay 28 - ETF Daily News |
 |
Citizens JMP Reiterates Buy Rating on Zevra Therapeutics (ZVRA), Keeps PTMay 27 - Yahoo |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q1 '25 | 20M | 1.3M | 19M | -3.1M | -5.4M | -0.060 |
| Q4 '24 | 12M | 1.4M | 11M | -36M | -17M | -0.690 |
| Q3 '24 | 3.7M | 2.3M | 1.4M | -33M | -29M | -0.690 |
| Q2 '24 | 4.4M | 3.6M | 880,000 | -20M | -16M | -0.480 |
| Q1 '24 | 3.4M | 3.3M | 160,000 | -17M | -14M | -0.400 |
Insider Transactions View All
| Watton Corey Michael filed to buy 1,800 shares at $7.8. March 31 '25 |
| Bode John B filed to buy 40,000 shares at $8. March 21 '25 |
| McFarlane Neil F. filed to sell 191,516 shares at $8.1. February 14 '25 |
| Sangiovanni Timothy J. filed to sell 16,341 shares at $7.9. February 14 '25 |
| McFarlane Neil F. filed to sell 222,060 shares at $7.9. February 14 '25 |
Similar companies
Read more about Zevra Therapeutics (ZVRA) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, news mentions, customer reviews & linkedin employees.
What is the Market Cap of Zevra Therapeutics?
The Market Cap of Zevra Therapeutics is $494M.
What is the current stock price of Zevra Therapeutics?
Currently, the price of one share of Zevra Therapeutics stock is $9.00.
How can I analyze the ZVRA stock price chart for investment decisions?
The ZVRA stock price chart above provides a comprehensive visual representation of Zevra Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Zevra Therapeutics shares. Our platform offers an up-to-date ZVRA stock price chart, along with technical data analysis and alternative data insights.
Does ZVRA offer dividends to its shareholders?
As of our latest update, Zevra Therapeutics (ZVRA) does not offer dividends to its shareholders. Investors interested in Zevra Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Zevra Therapeutics?
Some of the similar stocks of Zevra Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.